Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol Vanlev OCTAVE Trial Will Compare Angioedema To ACE Inhibitors

Executive Summary

Bristol's effort to resurrect the Vanlev NDA via the 25,000-patient OCTAVE trial will produce "the best look at angioedema for ACE inhibitors that has ever been compiled," Bristol VP-Corporate Development for the Worldwide Medicines Group Andrew Bodnar, MD, told a July 20 quarterly earnings conference call.
Advertisement

Related Content

Bristol Vanlev OCTAVE Data: Angioedema Risk Suggests Second-Line Use
Bristol Vanlev
Bristol Vanlev
Bristol Vanlev Launch Resources Will Shift To Pravachol; NDA Withdrawn
Bristol Vanlev Launch Resources Will Shift To Pravachol; NDA Withdrawn
Advertisement
UsernamePublicRestriction

Register

PS036407

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel